by ASTCT
The following infographics are based on ASTCT's December 2, 2026 webinar in which Dr. Michael D. Jain (Moffitt Cancer Center) and Dr. Stephen Gottschalk (St. Jude Children’s...
by Kevin McNerney, MD
Kevin McNerney, MD, is the first author of the article “Management practices of CAR T-cell-related inflammatory toxicities: a survey of pediatric CAR T-cell providers.” He shares in...
by Alex Kadhim
Researchers at McMaster University, collaborating with the Ottawa Hospital Research Institute, have found that a paired vaccine plus CAR strategy can broadly boost adoptively transferred T cells...
by Alex Khadhim
Researchers at University Hospital of Leipzig and Memorial Sloan Kettering Cancer Center have demonstrated that the BCMA CAR T product ciltacabtagene autoleucel appears to deliver deeper and...
by ASTCT Talks
In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD (The University of Texas MD Anderson Cancer Center; Pharmacy SIG Immediate Past-Chair), sits down with Zainab Shahid, MD (Memorial...
by Journal of Clinical Investigation
IFNγ blockade curtails the incidence of high-grade toxicities associated with chimeric antigen receptor (CAR) T-cell therapy, researchers report. Observations from a murine model of toxicities...